Clinical trials: Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Condition Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Funder type Industry (pharma, biotech, devices)
Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia
The study is a randomized, double-blind, placebo-controlled (corn oil), parallel group design that will enroll approximately 13,000 patients with hypertriglyceridemia and low HDL and high risk for CVD to be randomized 1:1 to…
- Trial name
- STRENGTH (NCT02104817)
- Testing
- Epanova® (omega-3 carboxylic acids), corn oil control
- Where
- 684 sites in United States, Australia and 20 more
- Volunteers
- 13,078 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)
The purpose of this 24 week study is to compare the effectiveness and safety of different doses of Niacin ER/Simvastatin (NS) in subjects with elevated fat levels in their blood (dyslipidemia).
- Trial name
- NCT00080275
- Testing
- Niacin Extended-Release and simvastatin Tablets
- Volunteers
- 600 people
- Sponsor
- Kos Pharmaceuticals
Hyperlipidemia
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects
The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with…
- Trial name
- GAUSS (NCT01375764)
- Testing
- Evolocumab, Ezetimibe
- Where
- 42 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Amgen
Cancer, Overall Survival
Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer
The purpose of this study is to determine the effectiveness of a regimen of selected metabolic treatments for patients with cancer in a real world setting and to conduct exploratory analysis on the relationship between the degree…
- Trial name
- METRICS (NCT02201381)
- Testing
- Metabolic treatment
- Where
- United Kingdom
- Sponsor
- Health Clinics Limited
Atherosclerosis, Inflammatory Activity in Coronary Arteries
Exploratory Study of Coronary Flow Reserve Measurements, a Non-Invasive Method for Coronary Function Measurements
The aim of this study is to investigate whether the non-invasive ultrasound method for assessment of coronary blood flow, transthoracic Doppler echocardiography-coronary flow reserve (TTDE-CFR), can be used to measure drug…
- Trial name
- NCT00783042
- Testing
- Rosuvastatin
- Where
- Sweden
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Dyslipidaemias, Dyslipidemias
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin
This study investigates the safety, pharmacokinetics and effects of GSK1292263 when taken alone or when co-dosed with atorvastatin to subjects with dyslipidemia.
- Trial name
- NCT01218204
- Testing
- 10mg atorvastatin, 80mg atorvastatin, 100mg GSK1292263
- Where
- 21 sites in United States
- Volunteers
- 287 people
- Sponsor
- GlaxoSmithKline
Elevated High-sensitivity C-Reactive Protein (hsCRP)
JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events
The purpose of this study is to determine the safety and effectiveness of long-term therapy with rosuvastatin compared with a placebo, and to evaluate whether treatment with rosuvastatin might be effective in reducing the risk of…
- Trial name
- NCT00239681
- Testing
- Rosuvastatin
- Where
- 856 sites in United States, Argentina and 25 more
- Volunteers
- 17,802 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4
The primary objective of the study was to evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in…
- Trial name
- GAUSS-4 (NCT02634580)
- Testing
- Evolocumab, Ezetimibe
- Where
- 35 sites in Japan
- Volunteers
- 61 people
- Sponsor
- Amgen
Cardiovascular Disease
Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
The aim of this study was to estimate the number of United States (US) adults with and without prior atherosclerotic cardiovascular disease (ASCVD) and diabetes who may be eligible for inclisiran based on US National Health and…
- Trial name
- NCT07214857
- Where
- United States
- Volunteers
- 1,385 people
- Sponsor
- Novartis Pharmaceuticals
Hypertriglyceridemia
Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)
The primary objective is to determine the efficacy of AMR101 (ethyl icosapentate) compared to placebo in lowering high fasting triglyceride levels in patients with high risk for cardiovascular disease and fasting triglyceride…
- Trial name
- ANCHOR (NCT01047501)
- Testing
- AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day
- Where
- 80 sites in United States
- Volunteers
- 702 people
- Sponsor
- Amarin Pharma Inc.
Hyperlipidemia
LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy
To evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab (AMG 145) administered every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on percent change from baseline in LDL-C when used in addition to a…
- Trial name
- LAPLACE (NCT01380730)
- Testing
- Evolocumab
- Where
- 100 sites in United States, Canada and 3 more
- Volunteers
- 631 people
- Sponsor
- Amgen
Hypercholesterolemia, Dyslipidemia
A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins
This study will investigate the effect of PF-04950615, a new investigational lipid lowering agent, on LDL-C and other lipids.
- Trial name
- NCT01342211
- Testing
- Statin, PF-04950615 (RN316), Satin
- Where
- 44 sites in United States, Canada
- Volunteers
- 93 people
- Sponsor
- Pfizer
Hypertriglyceridemia, Cardiovascular Disease
[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL
The primary objective is to evaluate the efficacy of adding Epanova (2 g or 4 g daily) to an optimal statin monotherapy for lowering non-high-density lipoprotein (non-HDL) cholesterol in subjects with persistent…
- Trial name
- ESPRIT (NCT01408303)
- Testing
- Olive oil, 4g, omega-3-carboxylic acids, 2g, omega-3-carboxylic acids, 4g
- Where
- 89 sites in United States
- Volunteers
- 646 people
- Sponsor
- AstraZeneca
Atherosclerotic Cardiovascular Disease
A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)
The purpose of this study was to assess the effectiveness of an "inclisiran first" implementation strategy (addition of inclisiran to maximally tolerated statin therapy immediately upon failure to achieve acceptable LDL-C with…
- Trial name
- V-INITIATE (NCT04929249)
- Testing
- Inclisiran
- Where
- 43 sites in United States
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia
Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED)
In the context of australian general practice, to determine the efficacy and safety of ezetimibe 10mg/statin 40mg coadministration in patients with uncontrolled cholesterol receiving statin 40mg or more.
- Trial name
- NCT00395473
- Testing
- MK0653, ezetimibe / Duration of Treatment: 6 Weeks
- Volunteers
- 141 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003
Randomized, double-blind, placebo-controlled, single ascending dose study in nine (9) separate and sequential dose cohorts (7 SC and 2 IV cohorts) to assess the safety and tolerability, pharmacokinetics and pharmacodynamics of…
- Trial name
- LIB003SAD (NCT03545438)
- Testing
- LIB003
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- LIB Therapeutics LLC
Hypercholesterolemia
Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia
The purpose of this study is to evaluate lapaquistat acetate, once daily (QD), taken alone or with additional statin therapy on cholesterol levels in treating patients with elevated cholesterol.
- Trial name
- NCT00249899
- Testing
- Lapaquistat acetate and stable statin therapy, Stable statin therapy
- Where
- 23 sites in United States, Canada and 1 more
- Volunteers
- 649 people
- Sponsor
- Takeda
Diabetes Mellitus
Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.
The purpose of this study is to measure the triglyceride changes in subjects with type 2 diabetes mellitus taking pioglitazone, once daily (QD), following treatment conversion from rosiglitazone.
- Trial name
- COMPLEMENT (NCT00672919)
- Testing
- Pioglitazone
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 305 people
- Sponsor
- Takeda
Hypercholesterolaemia, Hyperlipidaemia
TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)
In patients with primary hypercholesterolemia treated with a statin and with ldl-c above the recommended target goal (esc 2003 recommendations ldl>=1.15 g/l) to compare the efficacy and the safety of ezetrol added to ongoing…
- Trial name
- NCT00328523
- Testing
- MK-0653, ezetimibe, Duration of Treatment: 3 months
- Volunteers
- 1,496 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol
This study will evaluate the lipid-lowering effect and safety of colesevelam therapy administered to heterozygous familial pediatric patients 10 through 17 years of age who are on a stable dose of a pediatric-approved statin…
- Trial name
- NCT00145574
- Testing
- colesevelam HCl
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 194 people
- Sponsor
- Daiichi Sankyo